Pasar al contenido principal

Zamira Vanessa Diaz Riascos

I am a researcher in the Drug Delivery and Targeting (DDT) group, and our research is focused on improving the treatment of minority diseases such and cancer using nanomedicine in animal models. In addition, I am responsible for the in vivo section of the Functional Validation & Preclinical Research (FVPR) platform of the Nanbiosis U20.

Instituciones de las que forman parte

Investigador sénior
Direccionamiento y liberación farmacológica
Vall Hebron Institut de Recerca
Zamira Vanessa Diaz Riascos

Zamira Vanessa Diaz Riascos

Zamira Vanessa Diaz Riascos

Instituciones de las que forman parte

Investigador sénior
Direccionamiento y liberación farmacológica
Vall Hebron Institut de Recerca

I am a researcher in the Drug Delivery and Targeting (DDT) group, and our research is focused on improving the treatment of minority diseases such and cancer using nanomedicine in animal models. In addition, I am responsible for the in vivo section of the Functional Validation & Preclinical Research (FVPR) platform of the Nanbiosis U20.

I obtained the degree of Biology from the Autonomous University of Barcelona (Spain) in 2007. Also, in the same year I obtained the title of Official Master's Degree in Advanced Genetics from the Autonomous University of Barcelona. During my PhD in the laboratory of Dr. Gabriel Capellà (ICO-IDIBELL, Barcelona, Spain), I implanted an orthotopic mouse model, perpetuating human pancreatic ductal adenocarcinoma (PDAC) tissues. I gained a strong understanding of mouse surgery with considerable experience including: handling of clinical human samples, processing of samples derived from mouse models, and data analysis. My project focused on a molecular biology study characterizing the most frequent genes involved in this type of tumor. In addition, during my PhD I investigated the role of microRNAs, the miR-200 family, and ZEBs in PDAC primary tumors, patient-derived xenografts, and in cells that overexpress miR-200 by lentivirus transduction. I did an 11-month stay at the “Centre de recherches en cancerologie” of Toulouse, Inserm-Université Toulouse, France, under the supervision of Dr. Pierre Cordelier. Where I was trained to produce lentivirus, development of experiments with cell cultures and Western Blot analysis. Since 2016, I have been in the area of Functional Validation & Preclinical Research (FVPR) and I am currently responsible for the in vivo section, I also have a postdoctoral position in the Drug Delivery and Targeting group led by Dr. Abasolo. I have participated in multiple projects international and national studies using animal models for the validation of new therapeutic targets and new components of nanomedicine for cancer therapy. I recently participated in the development of the preclinical part of the Nocanther project, where magnetic hyperthermia in combination with chemotherapy was studied in a mouse model for the treatment of advanced pancreatic cancer. Nocanther is currently in the clinical phase. In addition, in these last 5 years, I have gained great experience in the field of lysosomal diseases, such as Fabry disease. In this case, I have studied the liposomes and extracellular vesicles as transport agents for the enzyme absent in this disease (GLA). I have carried out studies on the toxicity, biodistribution and efficacy of these nanoparticles in a GLA-deficient mouse model, obtaining published results. I am currently managing and maintaining a colony of transgenic mice. I also participate in a European project (Mimickey) that studies the disease of pycnodysosotosis (cathesin deficiency).
In addition, I have extensive experience in experimental imaging models and functional applications of bioluminescent or fluorescent non-invasive optical imaging. Work under ISO9001 conditions.

Líneas de investigación

Desenvolupament de models animals per l'avaluació ràpida i eficient de tractaments nanotecnològics

IP: Zamira Vanessa Diaz Riascos

Proyectos

Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)

IP: Ibane Abasolo Olaortua
Colaboradores: José Antonio Arranz Amo, Raquel Barquin Del Pino , Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Francisco Rodríguez Frias, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Francesc Martínez Trucharte, Pablo Gabriel Medina, Rosanna Paciucci Barzanti, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Beatriz Pacín Ruíz, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese
Entidad financiadora: AGAUR no fer servir-correcte 4301-37
Financiación: 60000
Referencia: 2021 SGR 01173
Duración: 01/01/2022 - 31/12/2024

Impacto y valor pronóstico de vesículas extracelulares tumorales provenientes de células madre cancerígenas en tumores de mama triple negativo.

IP: Joaquin Seras Franzoso
Colaboradores: Laura García Latorre, Diego Baranda Martínez-Abasca, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 99220
Referencia: PI22/01301
Duración: 01/01/2023 - 31/12/2025

Vesículas extracelulares para el tratamiento de enfermeades lisosomales (Título provisional)

IP: Ibane Abasolo Olaortua
Colaboradores: Laura García Latorre, Guillem Pintos Morell, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 153670
Referencia: PI21/00936
Duración: 01/01/2022 - 31/12/2024

MIMIC-KeY - A KEY TO THE RATIONAL DESIGN OF EXTRACELLULAR VESICLES-MIMICKING NANOPARTICLES.

IP: Ibane Abasolo Olaortua
Colaboradores: Joaquin Seras Franzoso, Guillem Pintos Morell, Zamira Vanessa Diaz Riascos
Entidad financiadora: EUROPEAN COMMISSION
Financiación: 457250
Referencia: MIMIC-KEY_H2020-FETPROACT-2020
Duración: 01/06/2021 - 31/05/2025

Noticias relacionadas

Hemos superado una exhaustiva evaluación externa de la OECI que nos acredita como centro de excelencia en la asistencia multidisciplinaria a los pacientes oncológicos, investigación, prevención, innovación y formación de los profesionales.

El proyecto de Joaquín Seras y Diana Fernandes de Sousa ha sido el ganador del certamen creado por la Asociación Cáncer de Páncreas (ACANPAN), la Asociación Española de Pancreatología (AESPANC) y la Asociación Española de Gastroenterología

Este año se celebrará el 10 y 11 de junio en la Rambla de Prim de Barcelona.

Profesionales relacionados

Rodrigo Berguenda Pinto

Rodrigo Berguenda Pinto

Administración y gerencia
Enfermedades Cardiovasculares
Leer más
Anna Maria Cueto Gonzalez

Anna Maria Cueto Gonzalez

Investigador/a principal
Medicina Genética
Leer más
Consuelo Garcia Carmona

Consuelo Garcia Carmona

Técnico de investigación
Fisiopatología Renal
Leer más
Rafael Esteban Mur

Rafael Esteban Mur

Investigador/a principal
Leer más

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Vall d'Hebron Barcelona Hospital Campus es un parque de referencia mundial donde la asistencia, la investigación, la docencia y la innovación se dan la mano.